Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Lung cancer: Molecular scissors determine therapy effectiveness

In the past few years, a number of anti-cancer drugs have been developed which are directed selectively against specific key molecules of tumor cells.

17 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Oncolytics Biotech Inc. has announced that it has started patient enrolment in a Phase 2 clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours.

12 Mar 2009

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Azaya Therapeutics, Inc. has announced that it has been selected by the National Cancer Institute (NCI) for a research collaboration to study Azaya's lead cancer therapy, ATI - 1123.

10 Mar 2009

Platinum-based anti-tumor compounds

Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

15 Feb 2009

Regular physical activity linked to better quality of life in early-stage lung cancer survivors

Survivors of early-stage lung cancer who take part in regular physical activity have a better quality of life, according to a study in the February issue of the journal Cancer Epidemiology Biomarkers and Prevention , available online now.

3 Feb 2009

Cream containing tretinoin associated with death in clinical trial, but relationship does not appear causal

Patients using a cream containing tretinoin, a retinoid commonly used to treat acne and other conditions, appeared more likely to die than those using a placebo in a clinical trial that was halted early as a result, according to a report in the January issue of Archives of Dermatology.

19 Jan 2009

Cell Therapeutics targeting potential Zevalin label expansion,

In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) reviewed 2009 targeted milestones and 2008 accomplishments.

15 Jan 2009

Diet high in inorganic phosphates increases risk of lung cancer

New research in an animal model suggests that a diet high in inorganic phosphates, which are found in a variety of processed foods including meats, cheeses, beverages, and bakery products, might speed growth of lung cancer tumors and may even contribute to the development of those tumors in individuals predisposed to the disease.

30 Dec 2008

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Oncothyreon Inc. announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately U.S. $13 million.

18 Dec 2008

Advance in K-Ras-mutated cancer research

A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches.

30 Nov 2008

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Why only some former smokers develop lung cancer

Canadian researchers are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar lifestyle changes.

17 Nov 2008

Tissue analyses indicate survival benefits for some lung cancer patients

Taking small tissue samples from patients with lung cancer and examining them under a microscope (a procedure called histology) is now being utilized to better tailor the chemotherapy treatments to improve survival in some patients with non-small cell lung cancer, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, cosponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Proton therapy may reduce serious side effect of lung cancer treatment

Patients with locally advanced lung cancer who receive chemotherapy and proton therapy, a specialized form a radiation therapy only available in a few centers in the United States, have fewer instances of a serious side effect called bone marrow toxicity than patients who receive chemotherapy and another type of radiation therapy called intensity modulated radiation therapy (IMRT), according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.

16 Nov 2008

Gender found to be play important role as a prognostic factor in people diagnosed with lung cancer

Even though some combinations of gender, race and/or marital status can factor into the overall survival of nonoperative non-small cell lung cancer patients, gender is the most significant factor impacting overall survival, according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancer

The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago.

16 Nov 2008

Non Small Cell Lung Cancer News and Research

Lung cancer: Molecular scissors determine therapy effectiveness

Biothera receives approval to launch two lung cancer trials

Oncolytics Biotech (TSX:ONC, NASDAQ:ONCY) starts U.S. enrolment in trial for non-small cell lung cancer patients

Azaya Therapeutics selected for Nanotechnology Characterization Lab by National Cancer Institute

Platinum-based anti-tumor compounds

Regular physical activity linked to better quality of life in early-stage lung cancer survivors

Cream containing tretinoin associated with death in clinical trial, but relationship does not appear causal

Cell Therapeutics targeting potential Zevalin label expansion,

Diet high in inorganic phosphates increases risk of lung cancer

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Advance in K-Ras-mutated cancer research

Gefitinib just as effective as chemotherapy for lung cancer

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Cancer drug bevacizumab linked to significantly increased risk of blood clots

Why only some former smokers develop lung cancer

Tissue analyses indicate survival benefits for some lung cancer patients

Proton therapy may reduce serious side effect of lung cancer treatment

Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment

Gender found to be play important role as a prognostic factor in people diagnosed with lung cancer

Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News